New cataract lens shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Minimum 22 years of age; 2. Bilateral cataracts for which posterior chamber IOL implantation has been planned; 3. Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with or without a glare source; 4. Potential for postoperative BCDVA of 20/30 Snellen or better; 5. Corneal astigmatism: 1. Normal corneal topography; 2. ≤ 1.0 D of preoperative keratometric astigmatism; 6. Clear intraocular media other than cataract; 7. Availability, ability, willingness and sufficient cognitive awareness to comply with examination procedures; 8. Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries; 9. Ability to understand and respond to a questionnaire in English. Exclusion Criteria: 1. Requiring an intraocular lens power outside the available range of +14.0 D to +26.0 D; 2. Any clinically significant pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils); 3. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.); 4. Prior corneal refractive surgery (SMILE, LASIK, LASEK, RK, PRK, etc.); 5. Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study; 6. Irregular corneal astigmatism; 7. Inability to achieve keratometric stability for contact lens wearers (as defined in preoperative procedures); 8. History of intraocular surgery, including prophylactic peripheral iridotomies and peripheral laser retinal repairs; 9. Recent ocular trauma that is not resolved/stable or may affect visual outcomes or increase risk to the subject; 10. Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study; 11. Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects; 12. Use of systemic or ocular medications that may affect vision; 13. Prior, current, or anticipated use during the 6-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcomes or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery); 14. Poorly controlled diabetes; 15. Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcomes of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable; 16. Known ocular disease or pathology that, in the opinion of the investigator: 1. may affect visual acuity; 2. may require surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.); 3. may be expected to require retinal laser treatment or other surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.); 17. Pregnancy, planned pregnancy, presently lactating or another condition associated with hormonal fluctuation that could lead to refractive changes; 18. Concurrent participation or participation within 30 days prior to preoperative visit in any other clinical trial; 19. Desire for monovision correction.